Bergen New Bridge To Begin 3rd COVID Vaccine Dose

News

Paramus NJ

16 August, 2021

12:22 PM

Description

PARAMUS, NJ — Bergen New Bridge will begin administering third doses of the Pfizer and Moderna COVID-19 vaccines this week for the immunocompromised. The Food and Drug Administration and Centers for Disease Control and Prevention approved the third dose of both vaccines for certain immunocompromised people, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to be an equivalent level of immunocompromised. According to Bergen New Bridge, moderately and severely immunocompromised people are eligible for the third dose. That definition includes: Active treatment for solid tumor and hematologic malignanciesReceipt of solid-organ transplant and taking immunosuppressive therapyReceipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplant or taking immunosuppression therapy)Moderate or severe primary immunodeficiency (e.g. DiGeorge, Wiscott-Aldrich syndromes)Advanced or untreated HIV infectionActive treatment with high-dose corticosteroids (i.e. >/=20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory3rd dose should be from the same manufacture as the patient's 1st and 2nd dose. Dose is given 4 weeks after 2nd dose (for both Pfizer and Moderna)Individuals should self-identify as moderately or Severely immunocompromised, no "proof" requiredThe same age limits for each manufacturer (12yrs+ for Pfizer and 18yrs+ for Moderna) apply for the 3rd dose as apply to the 1st and 2nd dosesThird doses will be available at New Bridge beginning Tuesday, and the vaccination center is open Tuesday through Thursday from 7 a.m. to 2:30 p.m. More registration information, click here.

By:  view source

Discussion

By posting you agree to the Terms and Privacy Policy.

/
Search this area